Jimin Health Announces Subsidiary Receives Patent Assignment Certificate for Oncolytic Adenovirus Therapy

Source: Financial Review Network

May 25,Chimin HealthAnnouncement: The controlling subsidiary, Hainan Jimin Boao International Hospital Co., Ltd., has completed the patent transfer procedures for "A Construction Method and Application of a Multi-Target Oncolytic Adenovirus" with Guangzhou Dabo Biological Products Co., Ltd., and received the "Notice of Eligibility for Procedures" issued by the China National Intellectual Property Administration.

The patent application date was September 28, 2023. The original patent holder was Guangzhou Dabo Biological Products Co., Ltd., and the current patent holder after the change is Hainan Jimin Boao International Hospital Co., Ltd. The patent transfer involves the DB006 oncolytic adenovirus injection project, which is currently in Phase I clinical trials, with indications focused on solid tumor-related diseases.

Special Statement: The above content only represents the author's viewpoint or position, and does not represent the viewpoint or position of Sina Finance Headlines. If you need to contact Sina Finance Headlines due to issues related to the work's content, copyright, or other matters, please do so within 30 days after the release of the aforementioned content.